A5103074030- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- RNA modifications and cancer
- Cancer Immunotherapy and Biomarkers
- Bone health and treatments
- Lung Cancer Research Studies
- Colorectal and Anal Carcinomas
- Ferroptosis and cancer prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
- Bone Metabolism and Diseases
- Lung Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Pancreatitis Pathology and Treatment
- Liver physiology and pathology
- Effects of Radiation Exposure
- Hernia repair and management
- Cancer Diagnosis and Treatment
- Tumors and Oncological Cases
- Bone fractures and treatments
- Appendicitis Diagnosis and Management
- Metastasis and carcinoma case studies
Sichuan University
2019-2025
Anshan Hospital
2024-2025
Guangdong Medical College
2024-2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2020-2025
West China Hospital of Sichuan University
2020-2025
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
2022
First Affiliated Hospital of Zhengzhou University
2014-2021
Weatherford College
2020
Dalian Medical University
2015
University of Pittsburgh
2001
Abstract Radiotherapy (RT) resistance in head and neck squamous cell carcinoma (HNSCC) significantly hampers local control patient prognosis. This study investigated the efficacy molecular mechanisms of high-energy X-ray-based ultra-high dose rate radiotherapy (UHDR-RT) overcoming RT resistance. The established RT-resistant HNSCC lines animal models were subjected to UHDR-RT or conventional (Conv-RT) via a high-power rhodotron accelerator. Cellular assays assessed malignant phenotype,...
Cell surface sialylation is emerging as an important feature of cancer cell multidrug resistance (MDR). We have focused on the influence 2,8-sialyltransferases in key steps development MDR chronic myeloid leukemia (CML). The expressional profiles six α-2,8-sialyltransferases were generated three pairs CML lines and peripheral blood mononuclear cells (PBMC) patients. Cellular phenotype positively correlated with ST8SIA4 ST8SIA6 levels. Furthermore, mediated activity phosphoinositide-3 kinase...
Background Synergistic anti-tumor effects were observed in vivo and vitro when immune checkpoint inhibitors (ICIs) combined with denosumab. However, the clinical benefit safety of this synergy have not been adequately evaluated non-small cell lung cancer (NSCLC). Methods Consecutive charts NSCLC patients bone metastases between December 2020 2021 Chinese National Cancer Center reviewed. The entire cohort was divided into one experimental group (denosumab + ICIs [DI]) three control groups...
Evidence on the influence of programmed death-ligand 1 (PD-L1) expression efficacy epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC) patients is at variance.A single-center retrospective study was conducted to evaluate PD-L1 EGFR-TKIs for NSCLC with EGFR mutation. Clinical information retrieved from electronic medical records. The were divided into three subgroups according level: < 1% (negative), 1%-49% and ≥ 50%....
(1) Background: Afatinib has been approved for patients with non-small cell lung cancer (NSCLC) carrying major uncommon epidermal growth factor receptor gene (EGFR) mutations. Dacomitinib, another second-generation tyrosine kinase inhibitor, also shown promising potential EGFR However, no comparative study conducted. (2) Methods: Two cohorts were employed: the AFANDA cohort, an ambispective cohort including 121 mutations admitted to two tertiary hospitals in China, and external validation...
Anoikis is a distinct type of programmed cell death and unique mechanism for tumor progress. However, its exact function in gastric cancer (GC) remains unknown. This study aims to investigate the anoikis-related lncRNA (ar-lncRNA) prognosis GC immunological infiltration. The ar-lncRNAs were derived from RNA sequencing data associated clinical information obtained Cancer Genome Atlas. Pearson correlation analysis, differential screening, LASSO Cox regression utilized identify typical with...
Abstract Background: Previous studies have suggested that the combination of RANKL inhibitors and immune checkpoint (ICIs) may potentiate therapeutic response in lung adenocarcinoma, particularly cases with KRAS mutations. The exact mechanisms clinical validation this therapy are yet to be fully understood. Methods: We conducted a comprehensive analysis by integrating public datasets retrospective data examine relationship between alterations tumor microenvironment KRAS-mutated...
Totally extraperitoneal (TEP) repair involves creating a preperitoneal space. The space can be created by telescopic dissection (TD) or plane (PD). Nevertheless, these techniques may have some complications. This study aims to assess the impact and comprehensively compare TD PD methods in patients undergoing laparoscopic TEP inguinal hernia repair. A retrospective analysis was conducted on 156 who underwent at Hospital from January 2017 December 2023. Using propensity score matching (PSM),...
Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical evidence of its activity on major uncommon EGFR mutations is currently limited. Materials and methods: This was a dual-center, single-arm, ambispective cohort study in China. Patients with histologically confirmed metastatic or recurrent NSCLC were eligible the study. The objective response rate disease control...
The acquired EGFR C797X mutation has been identified as the most notable resistance to osimertinib, and novel secondary mutations of L718 L792 residues have also demonstrated confer osimertinib resistance, making choice medication after treatment a quandary. Dacomitinib reported potential impact on patients acquiring rare compound resistance; however, little evidence is available date. In five lung adenocarcinoma resistant later-line recurrent at and/or were using targeted next-generation...
Background: Dacomitinib is a first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations; however, clinical evidence of its activity on NSCLC complex EGFR mutations limited. Methods: Patients (common co-existing uncommon mutations), or (comparison cohort) mutations, who were treated dacomitinib, retrospectively evaluated in the Chinese National Cancer Center and China PLA hospital between August 2019 2021....
Abstract This study aimed to identify the role of chromothripsis as a novel biomarker in prognosis and differentiation diagnosis pancreatic neuroendocrine neoplasms (pNENs). We conducted next‐generation gene sequencing cohort 30 patients with high‐grade (G3) pNENs. As reference, similar analysis was also performed on 25 low‐grade (G1/G2) tumors (pNETs). Chromothripsis its relationship clinicopathological features were investigated. The results showed that DNA damage response repair...
Gastric adenosquamous carcinoma (gasc) is a rare entity with distinctive characteristics that are not fully understood. In the present study, we evaluated of this disease.The U.S. Surveillance, Epidemiology, and End Results program database was searched to determine clinicopathologic features, prognostic factors, treatments for 246 patients gasc 42,735 gastric adenocarcinoma (gac).Relative gac, associated higher proportions cardia involvement, high-grade tumours, deep tumour invasion,...
Abstract Objective Dacomitinib has been approved for the first‐line treatment of non‐small cell lung cancer (NSCLC) carrying classical epidermal growth factor receptor ( EGFR ) mutations; however, real‐world data on its later‐line application are lacking. Materials and methods Patients’ were retrospectively collected from Chinese National Cancer Center PLA hospital between August 2019 2021. Kaplan‐Meier method Log‐rank test utilized to assess progression‐free survival (PFS) overall (OS)....
The primary factors that predispose humans to the development of alcoholic pancreatitis are unknown. One earliest observations in whom this disease develops is pancreatic hypersecretion caused by unknown mechanisms. Messenger RNA (mRNA) differential display was performed a rat model investigate molecular mechanisms associated with ethanol-induced hypersecretion. Male Wistar rats were pair-fed Lieber-DeCarli diets or without ethanol for 7 days 4 weeks. Total extracted from pancreas and its...
Abstract Objective Advanced lung cancers carrying Kirsten rat sarcoma viral oncogene homolog ( KRAS ) mutation remain a group that lacks effective treatments. Receptor activator of nuclear factorκB ligand RANKL has been demonstrated to drive malignant phenotypes in cancer; however, its role ‐mutant (mt) adenocarcinoma (LUAD) is not yet fully elucidated. Materials and methods The data used explore expression prognosis were obtained from Cancer Genome Atlas, Genotype‐Tissue Expression...
Human epidermal growth factor receptor 2 (HER2) has been verified as a valuable biomarker and treatment target in metastatic colorectal cancer (mCRC). Pyrotinib, novel irreversible HER2/epidermal (EGFR) dual tyrosine kinase inhibitor, can efficiently inhibit the proliferation of HER2-positive cells many tumors. We report case 40-year-old woman with both HER2- EGFR-amplified colon cancer, who developed refractory disease resistant to multiline therapies (including trastuzumab lapatinib) but...
9035 Background: Tumor angiogenesis could be induced by activation of HER2 receptor, and currently, there is lack clinical evidence anti-HER2 tyrosine kinase inhibitors (TKIs) combined with antiangiogenic therapy for HER2-mutant or amplified non-small cell lung cancer (NSCLC). We conducted a study to explore the efficacy safety pan-ErbB inhibitor pyrotinib apatinib metastatic NSCLC patients harboring amplification activating mutations. Methods: This was single-center, single-arm phase II...
Abstract Sarcoma is a rare malignancy with unfavorable prognoses. Accumulating evidence indicates that aberrant alternative splicing (AS) events are generally involved in cancer pathogenesis. The aim of this study was to identify the prognostic value AS-related survival genes as potential biomarkers, and highlight functional roles AS sarcoma. RNA-sequencing AS-event datasets were downloaded from Cancer Genome Atlas (TCGA) sarcoma cohort TCGA SpliceSeq, respectively. Survival-related further...